EP1296702A4 - Neuroprotektive peptide - Google Patents
Neuroprotektive peptideInfo
- Publication number
- EP1296702A4 EP1296702A4 EP01941562A EP01941562A EP1296702A4 EP 1296702 A4 EP1296702 A4 EP 1296702A4 EP 01941562 A EP01941562 A EP 01941562A EP 01941562 A EP01941562 A EP 01941562A EP 1296702 A4 EP1296702 A4 EP 1296702A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- neuroprotective peptides
- neuroprotective
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20765400P | 2000-05-26 | 2000-05-26 | |
US207654P | 2000-05-26 | ||
PCT/US2001/016654 WO2001091780A1 (en) | 2000-05-26 | 2001-05-23 | Neuroprotective peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1296702A1 EP1296702A1 (de) | 2003-04-02 |
EP1296702A4 true EP1296702A4 (de) | 2005-05-11 |
Family
ID=22771463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01941562A Withdrawn EP1296702A4 (de) | 2000-05-26 | 2001-05-23 | Neuroprotektive peptide |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1296702A4 (de) |
JP (1) | JP2003534384A (de) |
CN (1) | CN1318084C (de) |
AU (2) | AU2001274904B2 (de) |
BR (1) | BR0111182A (de) |
CA (1) | CA2410453A1 (de) |
HK (1) | HK1058484A1 (de) |
IL (1) | IL153079A0 (de) |
MX (1) | MXPA02011727A (de) |
NZ (1) | NZ522924A (de) |
WO (1) | WO2001091780A1 (de) |
ZA (1) | ZA200210304B (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235626B1 (en) | 1999-06-14 | 2007-06-26 | Genentech, Inc. | Structured peptide scaffold for displaying turn libraries on phage |
US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
PL2298347T3 (pl) | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
NZ543935A (en) * | 2003-05-12 | 2008-06-30 | Affymax Inc | Peptides that bind to the erythropoietin receptor |
EP2336162A1 (de) | 2003-05-12 | 2011-06-22 | Affymax, Inc. | Neue polyethylenglycol-modifizierte Agoniste von Erythropoietin und deren Verwendungen |
EP1628686A2 (de) * | 2003-05-12 | 2006-03-01 | Affymax, Inc. | Abstandsteil für mit poly (ethylenglycol) modifizierten peptide |
RS51130B (sr) * | 2003-05-12 | 2010-10-31 | Affymax Inc. | Novi peptidi koji se vezuju za eritropoietinski receptor |
US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
EP1848461A2 (de) | 2005-02-16 | 2007-10-31 | Nektar Therapeutics Al, Corporation | Konjugate einer epo-gruppierung und eines polymers |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
EP1857463A1 (de) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Neuroprotektive Wirkungen von Peptide |
CN101528263B (zh) | 2006-06-30 | 2013-01-23 | Sku资产管理有限公司 | 用于癌症的先天性免疫方法的缀合物 |
US8106154B2 (en) | 2007-01-31 | 2012-01-31 | Affymax, Inc. | Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules |
EP2018835B1 (de) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Wirkstoff abgebendes Pflaster |
KR20180041269A (ko) * | 2008-01-22 | 2018-04-23 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
MX2011008328A (es) | 2009-02-05 | 2011-11-04 | Immunogen Inc | Derivados novedosos de benzodiacepina. |
RU2410392C2 (ru) | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Дипептидные миметики нейротрофинов ngf и bdnf |
WO2012003960A1 (en) | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
DK2675479T3 (en) * | 2011-02-15 | 2016-04-11 | Immunogen Inc | cytotoxic benzodiazepine |
CA2918223A1 (en) * | 2013-07-17 | 2015-01-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CN105017406B (zh) * | 2014-04-21 | 2020-10-09 | 上海市第一人民医院 | 一类新的具有神经保护功能的多肽 |
CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
KR20210060536A (ko) | 2018-09-14 | 2021-05-26 | 에포-메드 가부시키가이샤 | 항에리트로포이에틴 수용체 펩티드 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
WO2000024782A2 (en) * | 1998-10-23 | 2000-05-04 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
-
2001
- 2001-05-23 AU AU2001274904A patent/AU2001274904B2/en not_active Ceased
- 2001-05-23 WO PCT/US2001/016654 patent/WO2001091780A1/en active IP Right Grant
- 2001-05-23 CA CA002410453A patent/CA2410453A1/en not_active Abandoned
- 2001-05-23 AU AU7490401A patent/AU7490401A/xx active Pending
- 2001-05-23 NZ NZ52292401A patent/NZ522924A/xx not_active IP Right Cessation
- 2001-05-23 MX MXPA02011727A patent/MXPA02011727A/es unknown
- 2001-05-23 EP EP01941562A patent/EP1296702A4/de not_active Withdrawn
- 2001-05-23 CN CNB018131794A patent/CN1318084C/zh not_active Expired - Fee Related
- 2001-05-23 BR BR0111182-5A patent/BR0111182A/pt not_active Application Discontinuation
- 2001-05-23 JP JP2001587795A patent/JP2003534384A/ja active Pending
- 2001-05-23 IL IL15307901A patent/IL153079A0/xx unknown
-
2002
- 2002-12-19 ZA ZA200210304A patent/ZA200210304B/en unknown
-
2004
- 2004-02-25 HK HK04101352A patent/HK1058484A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
WO2000024782A2 (en) * | 1998-10-23 | 2000-05-04 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
Non-Patent Citations (1)
Title |
---|
See also references of WO0191780A1 * |
Also Published As
Publication number | Publication date |
---|---|
ZA200210304B (en) | 2004-03-19 |
HK1058484A1 (en) | 2004-05-21 |
AU7490401A (en) | 2001-12-11 |
JP2003534384A (ja) | 2003-11-18 |
MXPA02011727A (es) | 2003-10-24 |
EP1296702A1 (de) | 2003-04-02 |
CN1452492A (zh) | 2003-10-29 |
IL153079A0 (en) | 2003-06-24 |
CN1318084C (zh) | 2007-05-30 |
CA2410453A1 (en) | 2001-12-06 |
BR0111182A (pt) | 2004-02-25 |
WO2001091780A1 (en) | 2001-12-06 |
AU2001274904B2 (en) | 2006-08-31 |
NZ522924A (en) | 2004-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ522924A (en) | Neuroprotective peptides | |
GB0014870D0 (en) | Peptides | |
IL146832A0 (en) | Peptides | |
SI1294381T1 (sl) | Neuroprotektivni 7-beta-hidroksi steroidi | |
GB0029777D0 (en) | Peptides | |
AU6268901A (en) | Oligopeptides | |
EP1159288A4 (de) | Alpha-conotoxin-peptide | |
EP1147130A4 (de) | Alpha-conotoxin-peptide | |
GB0001825D0 (en) | Peptides | |
GB0120713D0 (en) | Peptides | |
GB0007263D0 (en) | Peptides | |
EP1151100A4 (de) | Tau-conotoxin peptide | |
EP1323731A4 (de) | Neuartige peptide | |
GB0018307D0 (en) | Polypeptides | |
GB0021475D0 (en) | Anti-aniogenic peptides | |
GB0001826D0 (en) | Peptides | |
GB0010327D0 (en) | Peptides | |
GB0007264D0 (en) | Peptides | |
GB9928325D0 (en) | Peptides | |
GB9907911D0 (en) | Peptides | |
TJ20000630A (en) | Photosensetive material | |
GB0029850D0 (en) | Modifying material | |
GB0021877D0 (en) | Novel peptide sequence | |
GB0017431D0 (en) | Novel peptide sequence | |
GB0117737D0 (en) | Modified peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050322 |
|
17Q | First examination report despatched |
Effective date: 20070330 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110615 |